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Abstract
Background & Aims—Several small molecule inhibitors of the hepatitis C virus (HCV)
NS3/4A protease have advanced successfully to clinical trials. However, the selection of drug-
resistant mutants is a significant issue with protease inhibitors (PIs). A variety of amino acid
substitutions in the protease domain of NS3 can lead to PI resistance. Many of these significantly
impair the replication fitness of HCV RNA replicons. However, it is not known whether these
mutations also adversely affect infectious virus assembly and release, processes in which NS3 also
participates.
Methods—We studied the impact of 25 previously identified PI-resistance mutations on the
capacity of genotype 1a H77S RNA to replicate in cell culture and produce infectious virus.
Results—Most PI-resistance mutations resulted in moderate loss of replication competence,
although several (V36A/L/M, R109K, and D168E) demonstrated fitness comparable to wild type,
whereas others (S138T and A156V) were severely impaired both in RNA replication and
infectious virus production. Although reductions in RNA replication capacity correlated well with
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decreased yields of infectious virus for most mutations, a subset of mutants (Q41R, F43S, R155T,
A156S, and I170A/T) reproducibly demonstrated greater impairment in their ability to produce
virus than predicted from reductions in RNA replication capacity. More detailed examination of
the I170A mutant demonstrated no defect in release of virus from cells, and no significant
difference in specific infectivity of extracellular virus particles.
Conclusions—Replicon-based assays might underestimate the loss of fitness caused by PI-
resistance mutations, as some mutations in the NS3 protease domain specifically impair late steps
in the viral lifecycle that involve intracellular assembly of infectious virus.
Keywords
Antiviral drug; NS3/4A protease; viral assembly; viral replication
Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, frequently
culminating in liver cirrhosis and hepatocellular carcinoma. The current standard-of-care
therapy for patients with chronic hepatitis C is a combination of pegylated interferon-α and
ribavirin. However, it is only partially effective, as only about 50% of patients with
genotype 1 HCV infection achieve a sustained virological response1. Accordingly, there is
intense interest in developing novel, small-molecule, direct-acting antiviral compounds.
The HCV NS3/4A protease is a particularly promising target for direct-acting antiviral
therapies. Several chemical classes of NS3/4A protease inhibitors (PI) have been developed
that potently inhibit HCV replication. Two linear peptidomimetic ketoamides (telaprevir and
boceprevir) have entered phase 3 studies2–4, and several macrocyclic inhibitors (e.g.,
danoprevir, vaniprevir and TMC435) are in phase 2 development5–7. Despite this progress,
the selection, emergence, and persistence of drug-resistant viruses are significant concerns
with these antiviral compounds8, 9. Drug-resistant variants exist at varying frequencies in
untreated patients as part of the viral quasispecies10, 11. This reflects the highly replicative
nature of HCV infections as well as the error-prone nature of the HCV RNA-dependent
RNA polymerase12. Resistant viruese are rapidly selected and may become dominant
among the quasispecies under the pressure of antiviral exposure. Both in vitro and in vivo
studies have shown that a variety of amino acid substitutions within the NS3 protease
domain can lead to PI resistance, with the specific mutations dependent on both chemical
class and the individual compound (Supplementary Table 1).
While the impact of these mutations on resistance to NS3/4A inhibitors has been well
characterized, their impact on viral fitness, both in cell culture and in infected patients, is
less well understood. Viral fitness can be defined as the ‘relative ability of a virus to produce
infectious progeny’13. However, previous efforts to characterize the ‘fitness’ of PI-resistant
mutants in vitro have been limited to RNA replicons that are incapable of producing
infectious virus. Thus ‘fitness’ has generally been characterized in terms of ‘relative
replication capacity’. PI-resistant mutants often have inferior replication capacity in cell
culture. For example, a common PI-resistance mutation (A156T) in the NS3 protease
drastically reduces the capacity of replicons to replicate in cell culture14, 15. However,
replicons containing drug-resistance mutations are not universally impaired in their
replication capacity: replicons with V36A, Q41R, T54A, A156S, or I170A mutations have
been reported to replicate at least as well as replicons with wild-type NS3 sequence16–19.
The replication capacity of R155K was also similar to wild type in some reports17, 20, but
significantly reduced in others16.
A better understanding of the impact of PI-resistance mutations on the fitness of HCV is
important, since fitness is a critical factor in determining the probability with which mutants
will emerge, persist, and potentially cause disease in patients treated with PIs. Our aim here
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was to determine whether these mutations adversely affect the production of infectious virus
– a more definitive measure of viral fitness than used in prior studies. The NS3 helicase
domain is involved in an early step in the assembly of infectious virus particles21. While the
extent to which the protease domain of NS3 also contributes to assembly is unknown, it is
possible that PI-resistance mutations could adversely impact virus assembly as well as
polyprotein processing. To assess this possibility, we analyzed an extensive panel of PI
resistance mutations placed in the background of an infectious molecular clone of a
genotype 1a virus, pH77S.2, that when transfected as RNA into permissive cells replicates
efficiently and produces infectious virus. Our results confirm that most PI-resistance
mutations adversely impact the replication of HCV RNA, and in some cases also
specifically impair the production of infectious virus.
Materials and Methods
Cells and reagents
Details of the cells used in these studies are provided on-line in the Supplementary Materials
and Methods. Stock solutions of ciluprevir (BILN2061), boceprevir (SCH 503024),
danoprevir (ITMN-191), and vaniprevir (MK7009) were prepared in DMSO.
Plasmids
pH77S.3 is derived from pH77S22, an infectious molecular clone of a genotype 1a HCV,
and contains an additional cell culture-adaptive mutation in E2. When transfected into
permissive cells, genome-length RNA transcribed from pH77S.3 replicates efficiently and
produces virus that is infectious for naïve cells. To monitor replication, the Gaussia
luciferase (GLuc) sequence, fused at its C terminus to the FMDV 2A autoprotease, was
inserted between p7 and NS2 of pH77S.2. Detailed descriptions of these plasmids, cloning
procedures, and construction of PI resistant mutants are provided on-line in the
Supplementary Methods.
Viral Fitness
Fitness of the mutated HCV RNAs was determined by measuring the capacity of each to
replicate in transfected cells and also to produce infectious virus. Genome-length RNA was
synthesized in vitro and transfected into cells as described in detail in the Supplementary
Methods. Replication of the RNA was assessed by monitoring GLuc activity secreted into
the medium of transfected cells, or by northern analysis of extracted RNA. Yields of
infectious virus released into cell culture supernatant fluids were determined by a quantal
fluorescent focus assay. Details of these methods are provided on-line in the Supplementary
Methods. RNA replication capacity and infectious virus yields were normalized to those
produced by wild-type RNA in each experiment, and compared across the panel of NS3
mutants.
Antiviral activity assays
Antiviral activities were determined based on the ability of compounds to inhibit the
production of GLuc by HCV RNA-transfected cells. Further details are provided on-line in
the Supplementary Methods.
Statistical analysis
Student’s t test was used to compare the magnitude of the reductions in RNA replication
capacity and/or infectious virus yield imposed by PI mutations, after normalization to wild-
type controls.
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PI resistance profile of genotype 1a H77 virus
Since NS3 participates in the assembly of virus particles21, we set out to determine the
impact of PI-resistance mutations in NS3 on fitness of a molecular clone of genotype 1a
HCV, pH77S.3, a derivative of pH77S that contains cell culture-adaptive mutations and
produces fully infectious virus when transfected as RNA into Huh7 cells22. To facilitate
monitoring viral RNA replication, we inserted the Gaussia luciferase (GLuc) sequence isn
frame between the p7 and NS2 sequences of pH77S.3. Details concerning this construct and
validation of GLuc expression as a surrogate marker of the replication of RNA transcribed
from it are described in detail on-line in the Supplementary Methods and Results. To profile
resistance to PIs in this genotype 1a virus, we used site-directed mutagenesis to construct 25
different H77S.3/GLuc2A mutants, each with a specific amino acid substitution in NS3
reported previously to cause resistance in genotype 1b virus against at least one of 7
candidate PIs: ciluprevir (BILN2061), telaprevir (VX-950), boceprevir (SCH503034),
SCH446211 (Sch6), danoprevir (ITMN191), TMC435, or vaniprevir (MK7009)
(Supplementary Table 1). These mutations include those identified in vitro in replicon-based
studies in vitro and also in vivo, in clinical trials, and involve 11 different residues in the
protease domain of NS3. For the most part, these mutations have been studied previously
only in the context of genotype 1b replicons. To confirm that they also confer PI resistance
in a genotype 1a background, we assessed the ability of selected PIs (ciluprevir, boceprevir,
danoprevir and vaniprevir) to inhibit replication of a subset of the H77S.3/GLuc2A mutants.
Antiviral EC50 values were determined from the concentration of the compound required to
cause a 50% reduction in secretion of GLuc by RNA-transfected cells (see Supplementary
Methods). With the exception of R155Q, which did not lead to resistance against boceprevir
as expected, the mutations caused significant increases in the EC50 of one or more PI (Table
1). Because the EC50 of boceprevir against the wild-type H77S.3/GLuc2A construct (490
nM) was over 100-fold higher than that of the other PIs tested, the fold-change in the EC50
was generally less dramatic with this compound (Table 1). Notably, in two cases, S138T and
A156V, the RNA replication fitness of the genotype 1a mutant was so impaired as to
prevent a reliable measurement of the EC50 (see below).
Impact of PI-resistance mutations on RNA replication capacity
To determine the impact of the resistance mutations on the replication capacity of H77S.3/
GLuc2A RNA, we measured GLuc activity in media collected at 24h intervals following
transfection. The results, normalized to the activity present 8 hrs after transfection, allowed
classification of the 25 mutants into 4 groups based on RNA replication kinetics (Fig. 1).
The first of these groups, comprising the V36A/L/M, Q41R (H77S.2/GLuc2A), R109K,
D168E, and I170A mutants, demonstrated little loss of replication capacity, with fold-
increases in GLuc activity ≥85% of that observed with H77S.3/GLuc2A (Fig. 1, left panel).
A second group, comprising the majority of the mutants, demonstrated moderately impaired
replication capacity (GLuc activity <85% H77S.3/GLuc2A) but still generated GLuc
activities that increased continuously after transfection (Fig. 1, middle panel). A third group,
comprised of R155G, A156T, and D168G, demonstrated more severe impairments in
replication, with the GLuc activity at 48h consistently less than at 8h, but generally
increasing after 72h (Fig. 1, right panel, note the log scale for GLuc in this panel). A fourth
group, comprised only of S138T and A156V, was defined by the absence of any increase in
GLuc activity after 8–24h, and thus demonstrated GLuc expression similar to that observed
with the lethal AAG mutant (Fig. 1, right panel). These results show that the replication
competence of genotype 1a RNA is variably affected by PI-resistance mutations, with the
impact on replication ranging from none to very severe. Although some patterns were
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evident (see Discussion), loss of replication competence did not correlate strictly with the
specific NS3 residue involved or the magnitude of PI resistance (fold-change in EC50).
Impact of PI-resistance mutations on infectious virus production
We next assessed the impact of each of the PI-resistance mutations on production of
infectious virus by H77S.3 RNA. Cell culture supernatant fluids were collected 72h and 96h
after transfection were inoculated onto naïve cells, and foci of infected cells detected by
immunofluorescence 96h later. As shown in Figure 2, infectious virus yields varied
significantly among the different mutant RNAs, most often correlating closely with the
relative RNA replication capacity of the related H77S.3/GLuc2A mutant. This is not
surprising, as RNA replication is essential for production of infectious virus. However, 6
mutants (Q41R, F43S, R155T, A156S, I170A and I170T), demonstrated a reproducible
discordance between replication capacity (GLuc expression relative to wild-type) and
infectious virus yield (FFU/ml relative to wild-type) (Fig. 2). In replicate experiments, the
yields of infectious virus from these mutants were significantly less than expected from the
RNA replication assay results (p<0.001 by Student’s t test). These results suggest that this
subset of resistance mutations specifically impedes some aspect of infectious virus assembly
and/or release, above and beyond any negative effect of the mutation on genome
amplification. R155G and R155Q also demonstrated very substantial defects in production
of infectious virus that were greater than the observed defect in replication (Fig. 2). Thus
like the Thr substitution at Arg155 in R155T, Gly and Gln substitutions at residue 155 may
also negatively modulate the production of infectious virus. However, the replication of
these RNAs was so severely reduced that it was difficult to document an additional,
statistically significant defect in infectious virus yield.
To confirm that the discordance we observed between the impact of the Q41R, F43S,
R155T, A156S and I170A/T mutations on infectious virus yields from H77S.3 RNA and the
capacity of the mutated H77S.3/GLuc2A RNAs to replicate was not in some way related to
the GLuc2A insertion, we carried out two additional sets of experiments. First, we directly
assessed the production of infectious virus from the mutated H77S.3/GLuc2A RNAs,
comparing GLuc activity and infectious virus titer present in supernatant culture fluids
obtained from cells transfected with the mutated H77S.3/GLuc2A RNAs. We determined
the FFU/GLuc activity ratio of each mutant, and normalized this to that observed with the
wild-type H773.3/GLuc2A RNA that has no mutation in the NS3 protease domain. R109K
mutant, that has no defect in either RNA replication or infectious virus yield (Figs. 1 and 2),
was included as an additional control. These results (Fig. 3) confirmed that the R155T,
A156S and I170A/T mutations, placed in the H77S.3/GLuc2A background, result in reduced
production of infectious virus in addition to their impact on viral RNA replication. The F43S
and Q41R mutants appeared to have lesser specific defects in infectious virus yield, while
the R109K mutant produced infectious virus titers equivalent to wild-type, as anticipated.
We also compared infectious virus yields produced by the mutated parental H77S.3 RNAs
with viral RNA replication assessed directly by quantitative northern analysis. Virus yields
were determined in supernatant fluids collected 96h after transfection, at which time total
RNA was extracted from the cells for northern analysis. Northern blots (Fig. 4A) were
quantified by phosphor imaging, and the abundance of HCV RNA normalized to that of β-
actin included as a loading control. This provided an FFU/HCV RNA ratio for each mutant,
which was then normalized to that observed with wild-type H77S.3 RNA. The results of
these experiments (Fig. 4B) were remarkably similar to those shown in Fig. 2 and 3,
demonstrating that the yield of infectious virus, normalized to HCV RNA replication, was
substantially less than wild-type in the F43S, R155T, A156S, and I170A/T mutants. Q41R
demonstrated only a minor defect in the production of infectious virus (~20% reduced),
while R109K and D168H were similar to the wild-type H77S.3 RNA (Fig. 4B).
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To further assess the nature of the defect in infectious virus production, we selected the
I170A mutant that has significantly reduced infectious virus yield but no impairment in
RNA replication (Figs. 2–4). When compared with wild type, we found no difference in the
proportion of infectious I170A virus present within cell lysates and culture supernatant
fluids (Fig. 5A). Thus, the reduction in yield is not due to impaired release of infectious
virus from cells. We also compared the buoyant densities of the extracellular viruses by
equilibrium gradient centrifugation (see Supplemental Methods). Both the wild-type and
I170A viruses showed two major peaks of infectivity at ~1.062 and ~1.112 gm/cm3 (data not
shown), with the latter predominant. No significant differences were apparent in the specific
infectivity of the viruses present in these peak fractions (Fig. 5B). Collectively, these data
indicate that the I170A mutation results in a defect in intracellular infectious virus assembly.
Discussion
Despite progress in the clinical development of direct acting antiviral inhibitors of HCV
replication, the selection and persistence of drug resistant mutants remains a major concern
and will mandate the use of combinations of therapeutic agents in future treatment
regimes12. Given the highly replicative nature of HCV infection, with as many as 1012 new
genomes produced each day in the typical patient23, and the highly error-prone nature of the
HCV polymerase, viral RNAs harboring specific resistance mutations are likely to be
present within the RNA quasispecies prior to treatment in virtually all patients. Our data
(Fig. 1) and data from others14–20 suggest that most of these resistance mutations
negatively impact fitness; thus, viruses that harbor them represent a very small proportion of
the quasispecies pre-treatment. Nonetheless, these mutants may gain a significant growth
advantage over more prevalent drug-susceptible quasispecies upon the initiation of PI
therapy, leading to their emergence as dominant quasispecies. This is a major clinical
concern as direct acting antivirals enter the clinical armamentarium, making it important to
gain a better understanding of the impact of specific NS3 mutations on antiviral
susceptibility and replication fitness. Here, we have studied this in the context of a genotype
1a viral RNA (H77S.3) that replicates efficiently in cultured cells and produces virus that is
infectious in cell culture22 and in the chimpanzee model (see below). Our results show that
NS3 mutations conferring resistance against a variety of chemically diverse PIs have
variable impact on genotype 1a RNA replication, and provide novel evidence that a subset
of these mutations also specifically impair a later step in the virus life cycle involved in the
assembly of infectious virus.
The resistance mutations that we constructed in the genotype 1a H77S.3 background were
identified by a review of published data obtained from both cell culture-based and clinical
studies of PIs (Supplementary Table 2). Previous studies of the impact of PI-resistance
mutations on viral fitness generally have used subgenomic replicons derived from genotype
1b viruses, and have typically focused on small numbers of mutations selected by single PIs.
Our data are unique in that they are derived from studies of a full-length genotype 1a RNA,
and include analysis of a comprehensive panel of mutants selected by a variety of linear
ketoamide and macrocyclic inhibitors of NS3/4A in previous studies. As expected, we
confirmed that these mutations, introduced into the genotype 1a background, generally cause
resistance against PIs in the patterns expected (Table 1). Thus, we found a significant
increase in the EC50 of boceprevir, a linear ketoamide, for the V36G mutant, while the
D168A and D168V mutations markedly increased the EC50 for the macrocyclic compounds,
danoprevir, vaniprevir and ciluprevir, but not boceprevir (Table 1). Importantly, the R155T
and A156T mutations substantially increased the EC50 for each of the compounds tested.
Although some PI-resistance mutations, including V36A, Q41R, T54A, A156S and V170A,
have been suggested in prior studies to replicate more efficiently than related wild-type
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RNAs16–19, we did not observe this. H77S RNA containing Q41R (H77S.2) and I170A
mutations replicated as efficiently as wild-type virus (Figs. 1 and 4), but none of the mutants
we studied replicated significantly more efficiently than the wild type. This difference might
be due to the use of RNAs derived from different HCV strains, or possibly our use of
genome-length versus subgenomic RNA. In general, we found most resistance mutations
have a negative impact on replication of H77S.3 RNA (Fig. 1). There was little correlation
between loss of fitness, however, and the degree of antiviral resistance caused by specific
mutations. While D168A demonstrated greater resistance against danoprevir than D168G
(Table 1), D168G was severely compromised for replication while the loss of replication
competence was only moderate for D168A (Fig. 2). Similarly, R155T demonstrated robust
replication, yet caused very substantial increases in the EC50 for each of the PIs tested. This
likely reflects differences in how various PIs interact with the substrate-binding pocket in
the protease, and how this fit is impacted by the resistance mutation compared with binding
of the native polyprotein substrate. It is likely that the loss of RNA replication fitness stems
from reduced catalytic activity of the mutant protease, and therefore reduced competence in
processing of the viral polyprotein. Enzymatic activity is known to be sharply decreased
with the A156T mutation, and both subgenomic replicons14, 15 and genome-length H77S
RNA (Fig. 1) with this mutation show reduced replication capacity.
The most novel aspect of this study has been our ability to test the impact of PI-resistance
mutations on the production of infectious virus as well as RNA replication capacity. For
most mutants these measures of fitness correlated well, but in a subset of six mutants, i.e.,
Q41R, F43S, R155T, A156S, I170A and I170T, we observed a significantly greater negative
impact on the ability to produce infectious virus than on replication capacity Q41R and
I170A RNAs replicated as efficiently as wild-type H77S.3 RNA, but produced infectious
virus at rates that were ~20% and ~80% reduced. Although modest in magnitude, such
defects in infectious virus production are likely to be exponentially magnified during the
multiple cycles of cell infection occurring an infected patient. Importantly, of the subset of
resistance mutations causing such defects, all but Q41R have been identified in patients
enrolled in clinical trials of PIs (Table 1), making these results relevant to the setting in vivo.
Q41R is a particularly interesting mutation. We identified this early in the development of
the H77S clone as a cell-culture adaptive mutation24, and it is present in the H77S and
H77S.2 constructs (see Supplementary Fig. S1A). In a chimpanzee that was persistently
infected with virus produced by cells transfected with H77S.2 RNA, we observed a
complete reversion of this mutation, suggesting that the wild-type Gln41 residue is preferred
at this position in vivo. Although we found that H77S RNA encoding Arg41 replicated just
as efficiently as Gln41 (Figs. 1, 2 and 4), it had a small but reproducible impairment in
infectious virus production (Figs. 2, 3, and 4). This provides a potential explanation for the
reversion of the Q41R mutation during persistent infection, and an interesting in vivo
correlate of the findings in cell culture.
A comparison of intracellular and extracellular infectious virus titers indicated that the
reduction in yield of the I170A mutant is not due to impaired release of infectious virus from
the cell (Fig. 5A). Furthermore, within the range of experimental error, we could not
demonstrate any consistent difference in the specific infectivity of wild-type and I170A
viruses isolated on equilibrium density gradients (Fig. 5B). This suggests that the reduced
infectivity of extracellular fluids is not due to impaired virus entry.
The impaired catalytic activity observed with some resistance mutations reduces the ability
of the protease to cleave both TRIF and MAVS (unpublished data), cellular substrates of
NS3/4A that are essential adaptor proteins in signaling pathways that induce interferon
responses25. This could limit the ability of the virus to evade innate immune responses, and
possibly further impair viral RNA replication. However, the fact that wild-type and I170A
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viruses have similar specific infectivity (Fig. 5A) and identical RNA replication profiles in
transfected cells (Fig. 1, left panel) indicates that this is not the cause of the reduction
observed in production of infectious I170A virus (Fig. 2). Moreover, the disparities in RNA
replication and infectious virus production shown in Fig. 4 were observed in Huh-7.5 cells
that lack both TLR3 and RIG-I signaling. Collectively, the data point to a defect in virus
assembly.
It is likely that this defect in assembly of infectious virus is due to negative effects of the
mutations on essential protein-protein interactions, rather than reduced catalytic activity of
the protease as discussed above. NS3 interacts with multiple nonstructural proteins,
including NS2, and these interactions are important for production of infectious virus (Ma et
al., submitted for publication). Resistance mutations might also influence the structure or
function of the NS3 helicase domain, for which genetic evidence strongly supports a role in
particle assembly21. Consistent with this hypothesis, the NS3 residues at which we found
resistance mutations to have the greatest specific effect on production of infectious virus,
Arg155, Ala156, and Ile170 (Figs. 3 and 4), are nestled together on the surface of the protease,
at one edge of the substrate-binding site (Figs. 6A and B). This surface of the protease abuts
the helicase domain in the crystallographic structure of the full-length NS3 molecule26.
Although it is not known if NS3 actually adopts this conformation in vivo, prior studies do
suggest a modulating influence of the upstream protease domain on NS3 helicase activity27.
The two other residues within the protease domain that we found to influence production of
infectious virus, Gln41 and Phe43, are also surface-exposed, but on the opposing side of the
substrate-binding domain (Fig. 6B).
The data presented here represent an advance over previous studies of the fitness of PI-
resistant mutants in that they assess the impact of resistance mutations on steps in the viral
life cycle beyond RNA replication. They demonstrate that the use of replicon-based assays,
which assess only viral RNA replication, may significantly underestimate the loss of fitness
caused by some PI-resistance mutations. Nonetheless, caution is warranted in extrapolating
even from these data to the situation in vivo. The transient transfection assay we used here
did not allow for the emergence of compensatory mutations capable of rescuing the impaired
replication capacity of resistant viruses. In longer-term experiments, we have documented
such compensatory mutations in replicons containing the A156T mutation15. Antiviral drug
resistance will inevitably be an issue as PIs enter clinical practice, and continuing efforts
will be needed to monitor resistance and to relate data emerging from ongoing clinical
studies to results obtained using available in vitro systems.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Impact of drug-resistance mutations on genotype 1a HCV RNA replication
Medium was collected and replaced at 8, 24, 48, 72, 96, 120h after transfection of H77S.3/
GLuc2A RNAs carrying the indicated mutations, and GLuc activity determined at each
point in time. Results were normalized to the 8h GLuc activity, and represent the mean of
triplicate samples and are representative of multiple experiments. The mutants are grouped
in 3 panels, with increasingly negative impact on replication capacity from left to right.
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Figure 2. Impact of drug-resistance mutations on HCV RNA replication and infectious virus
production
GLuc activity secreted by RNA-transfected cells at 96 vs. 8 h, as shown in Fig. 1, was
normalized to that of the wild-type H77S.3 RNA (100% = 66 ± 19 fold-increase, lightly
shaded bars) and plotted adjacent to infectious virus yield (combined data from 72 and 96 hr
endpoints) from each mutant, similarly normalized to H77S.3 RNA (100% = 3.4 ± 1.3×103
FFU/ml, solid bars). The data shown represent the mean ± S.D. from at least three
(replication) or four (virus yield) independent experiments. An asterix [*] designates
mutants for which the difference between the relative capacities to replicate as RNA and to
produce infectious virus is significant by student’s t-test (p<0.001). “wt” refers to wild type.
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Figure 3. Infectious virus yield versus GLuc expression from H77S.3/GLuc2A mutants
Supernatant culture fluids were assayed for GLuc activity as well as infectious virus 96h and
120h following transfection of H77S.3/GLuc2A and related mutant RNAs. Results are
shown as the ratio of infectious virus to GLuc activity, normalized to wild-type H77S.3/
GLuc2A RNA (100% = 90 ± 12 FFU/ml/103 light units (L.U.) at 96h, and 88 ± 11 FFU/ml/
103 L.U. at 120h). Results are means ± S.D. from 3 experiments.
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Figure 4. Infectious virus yield vs. RNA abundance of H77S.3 mutants
H77S.3 and related RNAs containing the indicated mutations were transfected into Huh-7.5
cells. (A) Cells were lysed and total RNA extracted at 96h, then subjected to northern
blotting with HCV-and β-actin-specific probes. (B) Ratio of extracellular infectious virus at
96h to intracellular RNA abundance quantified by phosphor image analysis of northern blots
(HCV/β-actin RNA), normalized to yields from wild-type H77S.3 RNA (1.2 ± 0.52×103
FFU/ml). Results shown are means ± range from duplicate experiments.
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A PI resistance mutation causes a defect in assembly of infectious virus. (A) Intracellular
infectious virus titer as the percent of extracellular wild-type (H77S.3) and I170A virus 96h
after RNA transfection. Results are means ± S.D. (B) Specific infectivity of the major
species of extracellular wild-type (H77S.3) and I170A virus particles isolated by equilibrium
gradient centrifugation. Results are mean FFU/104 HCV genome equivalents (g.e.) ± S.E.M.
in 3 consecutive gradient fractions centered on each peak of infectivity.
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Structural model of the substrate-binding site in the genotype 1a NS3 protease domain
(PDB2OC0). (A) The surface depicted faces onto the NS3 helicase domain. The C-terminal
NS3 product of proteolysis is shown in orange ball-and-stick mode (created by
superimposing the structure from 1CU1). Residues where resistance mutations were
introduced are labeled and shown as yellow sticks. Catalytic residues are shown as red
sticks. The surface of the substrate-binding site is partially transparent. Surface coloring in
red and yellow highlights the surface involvement of catalytic residues and residues
involved in PI-resistance mutations, respectively. (B) Similar to panel A, but with the
surface now non-transparent, and with the surface residues that interact with the helicase
domain shown in dark blue. The C-terminal NS3 cleavage product is shown in ball-and-stick
mode (orange). Surface-exposed residues at which PI resistance mutations were introduced
in H77S.3 are colored in salmon and yellow. Those that specifically impact infectious virus
yield cluster in two areas on the surface of the protease adjacent to the substrate-binding
pocket.
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